

1                   **Epidemiologic Assessment of Pediatric Inflammatory Bowel Disease**  
2                   **Presentation in NYC During COVID-19**

3                   Janet Rosenbaum PhD<sup>1</sup>, Kenny Castro Ochoa MD<sup>2</sup>, Faria Hasan MD<sup>3</sup>, Alexa  
4                   Goldfarb DO<sup>4</sup>, Vivian Tang MD<sup>5</sup>, Gitit Tomer MD<sup>3</sup>, Thomas Wallach MD<sup>2</sup>

5  
6 **Affiliations:**

7                   <sup>1</sup>SUNY Downstate School of Public Health, Brooklyn, NY.

8                   <sup>2</sup>SUNY Downstate Health Sciences University, Department of Pediatrics,  
9                   Division of Pediatric Gastroenterology, Brooklyn, NY.

10                  <sup>3</sup>The Children's Hospital at Montefiore, Division of Pediatric  
11                  Gastroenterology Hepatology and Nutrition, Albert Einstein College of Medicine,  
12                  Bronx, NY.

13                  <sup>4</sup>New York University, Department of Pediatrics, Division of Pediatric  
14                  Gastroenterology, New York, NY.

15                  <sup>5</sup>Maimonides Medical Center, Department of Pediatrics, Division of  
16                  Pediatric Gastroenterology, Brooklyn, NY.

17  
18                  **Address correspondence to:** Thomas Wallach MD, Division of Pediatric  
19                  Gastroenterology, 450 Clarkson Ave, MSC 49. Brooklyn, NY, 11203.

20                  Fax: (718)270-198, Phone: (909)374-4350, Email: [Thomas.wallach@downstate.edu](mailto:Thomas.wallach@downstate.edu)

21  
22                  **Short title:** COVID-19 Impact on Pediatric IBD in NYC

23  
24                  **Conflict of Interest Disclosures:** The authors have no conflicts of  
25                  interest to report

26  
27                  **Funding/Support:** No funding was secured for this study.

28  
29                  **Role of Funder/Sponsor (if any):** none

30  
31                  **Abbreviations:** Ulcerative Colitis (UC), Crohn's Disease (CD), Inflammatory  
32                  Bowel Disease (IBD), New York City (NYC).

33  
34                  **Words:** 1886

38 **Contributors' Statement Page**

39

40 Dr. Wallach conceptualized the study and organized the consortium of institutions.  
41 Dr. Rosenbaum and Dr. Wallach designed the study, data collection instrument, and  
42 analytical framework. Drs Castro Ochoa, Tang, Tomer, Hasan, and Goldfarb collected data,  
43 organized local IRB approval at their respective institutions, and edited the manuscript. Dr.  
44 Rosenbaum harmonized, cleaned, and analyzed the data. Dr. Castro Ochoa, Dr.  
45 Rosenbaum, and Dr. Wallach wrote the manuscript. All authors reviewed, revised, and  
46 approved the final manuscript as submitted and agree to be accountable for all aspects of  
47 the work.

48

49

50 **Abstract:**

51 SARS-nCoV2 may have increased capacity to generate autoimmune disease; multiple  
52 reports suggest increased risk of Type 1 Diabetes, and case reports suggest other  
53 autoimmune linkages. Inflammatory Bowel Disease (IBD) pathogenesis appears to be a  
54 mix of genetic susceptibility, microbial populations, and immune triggers such as  
55 infections. Given the perceived role of infection in pathogenesis, decreased incidence of all  
56 infections during the pandemic secondary to non-pharmaceutical interventions should  
57 decrease IBD incidence rates. The aim of this study was to evaluate the association  
58 between the Covid-19 pandemic and IBD presentation in NYC using data from new  
59 diagnoses at a consortium of institutions.  
60 Using EMR systems all diagnoses at 4 collaborating institutions were retrieved from 2015-  
61 2021. We fit time series model (ARIMA) to the quarterly number of cases of each disease  
62 for January 2016-March 2020 and forecast the subsequent 21 months. We not only did not  
63 observe a decline in pediatric IBD secondary to absent viral illness but noted a statistically  
64 significant increase in Crohn's Disease approximately 6 months after the initial 2020  
65 COVID wave in NYC, and trends suggesting increases overall in IBD diagnoses above the  
66 existing trend towards increased disease presentation that pre-dated the pandemic. This  
67 data suggests that there may be a linkage between SARS-nCoV2 infection rates and  
68 subsequent pediatric IBD presentation, warranting further evaluation in the aftermath of the  
69 Omicron wave.

70

71 **Introduction**

72 The SARS-nCoV2 pandemic has created multiple challenges, but emerging data  
73 suggests additional possible long-term complications in the form of increased presentation  
74 of autoimmune diseases. Multiple Analytic studies have demonstrated Type 1 Diabetes  
75 diagnoses linked with SARS-nCov2 emergence, and case series suggest other autoimmune  
76 linkages<sup>1-3</sup>. Inflammatory Bowel Disease (IBD) is an autoimmune condition typically  
77 presenting in late childhood and young adulthood, with pathogenesis thought to be a mix  
78 of genetic susceptibility, microbial populations, and immune triggers such as infections<sup>4</sup>.  
79 Given the hypothesized role of infection in pathogenesis, decreased incidence of all  
80 infections during the pandemic secondary to non-pharmaceutical interventions (NPI)  
81 would likely be expected to generate a decrease in IBD incidence<sup>4,5</sup>. As the first US locus  
82 of a major SARS-nCoV2 outbreak, New York City represents a unique opportunity to  
83 identify any signal of altered IBD presentation secondary to infection and the NPI

84 implemented to manage the pandemic. This study will evaluate any association between  
85 the Covid-19 pandemic and new IBD diagnoses in NYC using data from a consortium of  
86 institutions.

87

## 88 **Methods**

### 89 **Data**

90 After institutional review board approval of respective institutions, we extracted  
91 date of diagnosis for Crohn’s Disease (CD) (n=349) and Ulcerative Colitis (UC) (n=145)  
92 patients presenting in pediatric GI clinic diagnosed 2016-2021 from electronic health  
93 records (EHRs).

### 94 **Measures**

95 Date of diagnosis was coded as year and month of diagnosis with the day removed  
96 for identifiability reasons. We measured the following demographic variables: year and  
97 month of birth and EHR-recorded sex (always or almost always sex assigned at birth). Age  
98 at diagnosis was measured in years; was at median 14.0 years (range 2-21 years) and was  
99 available for all patients. For two institutions, we were able to extract race, ethnicity, and  
100 zip code. Gender was a free entry field, and only male and female patients were present in  
101 the data; 44.0% were female and 56.0% were male.

102 Race and ethnicity were measured by a free-entry field, and race was available for  
103 30% of the participants and ethnicity for 44% of participants. Race was coded as White for  
104 free entry fields of White, and coded Black for free entry fields including Black, African  
105 American, and the typographical error “Afriac-American” [sic]. Race was coded as  
106 missing for declined, unavailable, or blank. Ethnicity was coded as Hispanic for free entry  
107 fields including Dominican, Mexican, Hispanic, Latino unspecified, Chicano/a, Puerto  
108 Rican, Salvadoran, South American, Spaniard, and Spanish. Participant ethnicity was coded  
109 as missing for entries of Declined, blanks, not applicable, not known, unknown n/a,  
110 unavailable.

111 An individual-level association between covid-19 infection and IBD would give the  
112 strongest inference, so we gathered data about past Covid-19 infection, measured as EMR  
113 record of either a positive-Covid-19 antibody test or positive Covid-19 PCR test. However,  
114 only one patient tested positive for antibodies and only one patient tested positive by PCR,  
115 so these measures were not used. Children were under-tested (cite) and tests may not  
116 appear in their EHR where they received IBD diagnosis because they may have been tested  
117 at school, public hospital system, urgent care clinics, or health systems that do not

118 contribute to these EHR systems.

119

## 120 **Analysis**

121 Due to potentially different seasonal variation and time to presentation, we  
122 analyzed CD and UC separately and excluded 22 cases of indeterminate IBD.

123 Using April 2020 as the first month of the covid-19 pandemic, we compared pre-  
124 pandemic versus pandemic periods with the Pearson chi-square test and pairwise  
125 proportion tests with Holm's correction. We fit an autoregressive integrated moving  
126 average model (ARIMA) to the quarterly number of cases of each disease for January  
127 2016-March 2020 and forecast the subsequent 21 months (April 2020-December 2021)  
128 with 80% and 95% prediction intervals using the forecast library.<sup>5</sup> The model for  
129 ulcerative colitis was ARIMA(1,0,0) with a mean of 1.91 cases per month (se=0.28), lag-1  
130 autocorrelation (AR1) of 0.30 (se=0.13), residual standard deviation of 2.00. The forecast  
131 varied only slightly across the interval. For ulcerative colitis, beginning in August 2020 an  
132 average of 1.90 cases were forecast with 80% prediction interval (0.00, 3.80) and 95%  
133 prediction interval (-1.00, 4.81).

134 The model for Crohn's disease was ARIMA(0,0,0) (white noise) with mean of 4.65  
135 cases per month (se = 0.37) and residual standard deviation of 7.07. Mean absolute scaled  
136 error is less than 1, which means the model is better than the naïve model (repeating  
137 previous year.) The forecast was uniform across the interval because the number of  
138 Crohn's disease cases per month were white noise. For Crohn's disease, an average of  
139 4.65 cases was forecast with 80% prediction interval (1.24, 8.06) and 95% prediction  
140 interval (-0.57, 9.86).

141 We evaluated the robustness of results to monthly versus quarterly time period and  
142 in a larger year span, using 2011-2021 data from 3 contributing institutions (Appendix).

143 To show seasonal patterns in diagnoses, we plotted total cases by month with loess  
144 regression and 95% confidence intervals using ggplot2 stratified by pandemic versus pre-  
145 pandemic diagnosis.<sup>6</sup> Residual plots showed no substantial departures from normality or  
146 evidence of heteroskedasticity. The Durbin-Watson statistic showed no evidence of  
147 autocorrelation for Crohn's disease for either period or for Ulcerative Colitis for the  
148 SARS-nCoV2 pandemic period.

## 149 **Results**

150 Patients diagnosed during the pandemic did not differ in demographic  
151 characteristics from patients diagnosed before the pandemic (**Table 1**). Downstate had a

152 larger share of cases during the pandemic (9.6% of cases at the 4 institutions) than before  
153 the pandemic (4.3% of cases) and Maimonides had a smaller share of cases during the  
154 pandemic (10.2% of cases) than before the pandemic (17.5% of cases) ( $p=0.03$ ); there  
155 were no significant differences between other institutions. Gender, age at diagnosis,  
156 diagnosis, county of residence, race, and ethnicity did not differ pre-pandemic versus post-  
157 pandemic.

158 We noted more CD diagnoses than expected in June and July during the pandemic  
159 compared with before the pandemic in the loess plots **[Figure 1]**.

160 We noted more CD cases than forecast in the third quarter of 2020, which had 26  
161 cases compared with upper limit of 95% prediction interval of 23.0 in ARIMA analysis  
162 **[Figure 2]**. We notice a trend towards elevation in UC diagnoses over time. Robustness  
163 checks using monthly data demonstrated similar rates exceeding 95% prediction in CD  
164 (July and September of 2020) and for UC in May and October of 2021, consistent with an  
165 elevation of mean monthly diagnoses.

166 As a first robustness check, we repeated the model with monthly data (2016-2021)  
167 **[Figure 3]**. The model for monthly ulcerative colitis was ARIMA (1,0,0) with a mean of  
168 1.91 cases per month ( $se=0.28$ ), lag-1 autocorrelation (AR1) of 0.30 ( $se=0.13$ ), residual  
169 standard deviation of 2.00. The forecast varied only slightly across the interval. For  
170 ulcerative colitis, beginning in August 2020 an average of 1.90 cases were forecast with  
171 80% prediction interval (0.00, 3.80) and 95% prediction interval (-1.00, 4.81). The model  
172 for Crohn's disease was ARIMA (0,0,0) (white noise) with mean of 4.65 cases per month  
173 ( $se = 0.37$ ) and residual standard deviation of 7.07. Mean absolute scaled error is less than  
174 1, which means the model is better than the naïve model (repeating previous year.) The  
175 forecast was uniform across the interval because the number of Crohn's disease cases per  
176 month were white noise. For Crohn's disease, an average of 4.65 cases was forecast with  
177 80% prediction interval (1.24, 8.06) and 95% prediction interval (-0.57, 9.86). We notice  
178 more ulcerative colitis cases than forecast in May 2021 and October 2021, which had 5  
179 cases each compared with upper limit of 95% prediction interval 4.81, and more Crohn's  
180 disease cases than forecast in July 2020 (12 cases), September 2020 (10 cases), compared  
181 with upper limit of 95% prediction interval 9.86.

182 As a second robustness check, we repeated the model with monthly and quarterly  
183 data from 2011-2021, which were available for 3 of the 4 institutions. **Table 2** compares  
184 the demographic data for these 3 institutions: as before, we notice that Downstate had  
185 more cases than usual during the pandemic than before the pandemic, and Maimonides

186 had fewer, but there were no other differences; these three institutions do not report  
187 Hispanic ethnicity.

188 The pre-pandemic model for quarterly ulcerative colitis was ARIMA(0,0,0)  
189 [Figure 4] with a mean of 2.81 cases per quarter (se = 0.28) and residual standard  
190 deviation of 2.88. The pre-pandemic model for quarterly Crohn's disease was  
191 ARIMA(0,0,0) with a mean of 7.22 cases per quarter (se = 0.54) and residual standard  
192 deviation of 11.2. Mean absolute scaled error for the pandemic data for UC and CD were  
193 0.92 and 0.82, which are less than 1, which mean the models are better than the naïve  
194 model (repeating previous year.)

195 With these three institutions, we notice more Crohn's disease than forecast in the  
196 third quarter of 2020 which had 14 cases compared with upper limit of 95% prediction  
197 interval of 13.8, and more ulcerative colitis than forecast in the fourth quarter of 2021,  
198 which had 8 cases compared with upper limit of 95% prediction interval of 6.1. We notice  
199 a trend towards elevation in UC diagnoses over time.

## 200 **Discussion**

201 Decreases in viral infection did not decrease CD and UC presentation rates,  
202 suggesting either diminished importance of viral infection as a pathogenic trigger of IBD  
203 or a strong capacity for SARS-nCoV2 to drive IBD pathogenesis. Second, we observe a  
204 significant increase in CD diagnoses with a possible temporal linkage of 4-6 months after  
205 pre-omicron peak SARS-nCoV2 infection in NYC in March/April 2020.

206 Our study has several limitations. IBD does not present with consistent patterns,  
207 resulting in wide variability in data. The 4-6 month lag between the city's peak infection  
208 rate and CD is more consistent with a SARS-nCoV2 infection pathogenesis than with  
209 delayed presentation from cases during the lockdown period. Our data does not include all  
210 pediatric gastroenterology groups in NYC, which may create effects due to variations in  
211 patient choice of providers.

212 Our study suggests a risk that large increases of SARS-nCoV2 infection in  
213 pediatric patients may drive increases in IBD diagnoses, in particular CD. Given recent  
214 widespread infection during the omicron wave, this study highlights the necessity of  
215 follow-up investigation of changes in incidence using existing data infrastructure.



## Acknowledgments

We would like to acknowledge the contributions of the following individuals, Dalia Arostegui MD, Chika Oragui MD, Agata Mann MD, Jon Dooley MD, and Dr. Melanie Greifer MD who assisted in data collection, and Steven Schwarz MD who assisted in building our data gathering collaboration.

## References

1. Gottesman BL, Yu J, Tanaka C, et al. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. *JAMA Pediatrics* 2022.
2. Saad MA, Alfshawy M, Nassar M, et al. COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases. *Curr Rheumatol Rev* 2021;17:193-204.
3. Barrett CE KA, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021. Volume 71. *MMWR Morb Mortal Wkly Rep*, 2022:59-65.
4. Sun L, Nava GM, Stappenbeck TS. Host genetic susceptibility, dysbiosis, and viral triggers in inflammatory bowel disease. *Curr Opin Gastroenterol* 2011;27:321-7.
5. Sullivan SG, Carlson S, Cheng AC, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. *Euro Surveill* 2020;25.

**Figure 1. Loess plots of UC and CD presentation by month.** A) Seasonal Loess plot of Ulcerative Colitis presentation by calendar month including all datapoints from 2016-2021. B) Seasonal Loess plot of Crohn's Disease presentation by calendar month including all datapoints from 2016-2021



**Figure 2. Time series (ARIMA) of UC and CD.** A) ARIMA time series analysis of UC presentation by 3 month period from 2016-2021 with 80% and 95% prediction intervals. B) ARIMA time series analysis of CD presentation by 3 month period from 2016-2021 with 80% and 95% prediction intervals.






Figure 4: Time series with prediction intervals (PI) forecast: quarterly ulcerative colitis (UC) and Crohn's disease (CD) cases, 2011-2021.




Figure 5: Time series with prediction intervals (PI) forecast for 3 institutions: monthly ulcerative colitis (UC) and Crohn's disease (CD) cases.




Table 1: Demographics of participants (2016-2021): All percentages are column percentages. 90

	All participants	Jan. 2016 – Mar. 2020	April 2020 – Dec. 2021	P-value
N	516	349	167	
<b>Gender</b>				0.6
Male	295 (57.2%)	196 (56.2%)	99 (59.3%)	
Female	221 (42.8%)	153 (43.8%)	67 (40.7%)	
<b>Age at diagnosis</b>				0.8
0-4	19 (3.7%)	13 (3.7%)	6 (3.6%)	
5-12	164 (31.8%)	114 (32.7%)	50 (29.9%)	
13-17	266 (51.6%)	180 (51.6%)	86 (51.5%)	
18-21	67 (13.0%)	42 (12.0%)	25 (15.0%)	
<b>Institution</b>				0.02
Downstate	31 (6.0%)	15 (4.3%)	16 (9.6%)	
Maimonides	78 (15.1%)	61 (17.5%)	17 (10.2%)	
Montefiore	236 (45.7%)	155 (44.4%)	81 (48.5%)	
NYU	171 (33.1%)	118 (33.8%)	53 (31.7%)	
<b>Race</b>				0.6
White	106 (20.5%)	76 (21.8%)	30 (18.0%)	
Black	45 (8.7%)	29 (8.3%)	16 (9.6%)	
Other or not reported	365 (70.7%)	244 (69.9%)	121 (72.5%)	
<b>Hispanic ethnicity</b>				0.6
Not Hispanic	121 (23.4%)	83 (23.8%)	38 (22.9%)	
Hispanic	110 (21.3%)	70 (20.1%)	40 (24.0%)	
Not reported	285 (55.2%)	196 (56.2%)	89 (53.3%)	
<b>Year of diagnosis</b>				n.a.
2016	67 (13.0%)	67 (19.2%)	0 (0%)	
2017	84 (16.3%)	84 (24.1%)	0 (0%)	
2018	80 (15.5%)	80 (22.9%)	0 (0%)	
2019	90 (17.4%)	90 (25.7%)	0 (0%)	
2020	96 (18.6%)	28 (8.0%)	68 (40.7%)	
2021	99 (19.2%)	0 (0%)	99 (59.3%)	
<b>Diagnosis</b>				0.7
Crohn's Disease	349 (67.6%)	237 (67.9%)	112 (67.1%)	
Ulcerative Colitis	145 (28.1%)	98 (28.1%)	47 (28.1%)	
Undetermined	20 (3.9%)	12 (3.4%)	8 (4.8%)	
Not reported	2 (0.4%)	2 (0.6%)	0 (0%)	
<b>Location</b>				0.4
Manhattan	31 (6.0%)	20 (5.7%)	11 (6.6%)	
Brooklyn	206 (39.9%)	148 (42.4%)	58 (34.7%)	
Queens	21 (4.1%)	12 (3.4%)	9 (5.4%)	
Bronx	151 (29.3%)	100 (28.6%)	51 (30.5%)	
Staten Island	11 (2.1%)	6 (1.7%)	5 (3.0%)	
Westchester	42 (8.1%)	28 (8.0%)	14 (8.4%)	
Rockland	30 (5.8%)	18 (5.2%)	12 (7.2%)	
Long Island	11 (2.1%)	10 (2.9%)	1 (0.6%)	
Other NY or PA or CT or NJ	5 (1.0%)	2 (0.6%)	3 (1.8%)	
Not reported	8 (1.6%)	5 (1.4%)	3 (1.8%)	

P-value from chi-square test of association between time period (pre-pandemic versus pandemic) and each variable.

Table 2: Demographics of participants at 3 institutions, 2011-2021

	All participants	Jan. 2011 – Mar. 2020	April 2020 – Dec. 2021	P-value
N	466	380	86	
<b>Gender</b>				0.6
Male	258 (55.4%)	208 (54.7%)	50 (58.1%)	
Female	208 (44.6%)	172 (45.3%)	36 (41.9%)	
<b>Age at diagnosis</b>				0.6
0-4	6 (1.3%)	4 (1.1%)	2 (2.3%)	
5-12	166 (35.6%)	137 (36.1%)	29 (33.7%)	
13-17	258 (55.4%)	212 (55.8%)	46 (53.5%)	
18-21	36 (7.7%)	27 (7.1%)	9 (10.5%)	
<b>Institution</b>				0.004
Downstate	42 (9.0%)	26 (6.8%)	16 (18.6%)	
Maimonides	110 (23.6%)	93 (24.5%)	17 (19.8%)	
NYU	314 (67.4%)	261 (68.7%)	53 (61.6%)	
<b>Race</b>				0.4
White	84 (20.5%)	70 (18.4%)	14 (16.3%)	
Black	7 (8.7%)	7 (1.8%)	0	
Other or not reported	375 (70.7%)	303 (79.7%)	72 (83.7%)	
<b>Hispanic ethnicity</b>				n.a.
Not Hispanic	0	0	0	
Hispanic	31 (6.7%)	23 (6.1%)	8 (9.3%)	
Not reported	435 (93.3%)	357 (93.9%)	78 (90.7%)	
<b>Year of diagnosis</b>				n.a.
2011	33 (7.1%)	33 (8.7%)	0 (0%)	
2012	27 (5.8%)	27 (7.1%)	0 (0%)	
2013	34 (7.3%)	34 (8.9%)	0 (0%)	
2014	36 (7.7%)	36 (9.5%)	0 (0%)	
2015	56 (12.0%)	56 (14.7%)	0 (0%)	
2016	39 (8.4%)	39 (10.3%)	0 (0%)	
2017	45 (9.7%)	45 (11.8%)	0 (0%)	
2018	43 (9.2%)	43 (11.3%)	0 (0%)	
2019	53 (11.4%)	53 (13.9%)	0 (0%)	
2020	50 (10.7%)	14 (3.7%)	36 (41.9%)	
2021	50 (10.7%)	0 (0%)	50 (58.1%)	
<b>Diagnosis</b>				0.3
Crohn's Disease	327 (70.2%)	267 (70.3%)	60 (69.8%)	
Ulcerative Colitis	126 (27.0%)	104 (27.4%)	22 (25.6%)	
Undetermined	10 (2.1%)	6 (1.6%)	4 (4.7%)	
Not reported	3 (0.6%)	3 (0.8%)	0 (0%)	
<b>Location</b>				0.2
Manhattan	49 (10.5%)	38 (10.0%)	11 (12.8%)	
Brooklyn	313 (67.2%)	257 (67.6%)	56 (65.1%)	
Queens	31 (6.7%)	23 (6.1%)	8 (9.3%)	
Bronx	6 (1.3%)	4 (1.1%)	2 (2.3%)	
Staten Island	13 (2.8%)	9 (2.4%)	4 (4.7%)	
Westchester	4 (0.9%)	4 (1.1%)	0	
Rockland	14 (3.0%)	10 (2.6%)	4 (4.7%)	
Long Island	24 (5.2%)	23 (6.1%)	1 (1.2%)	
Other NY or PA or CT or NJ	5 (1.1%)	5 (1.3%)	0	
Not reported	7 (1.5%)	7 (1.8%)	0	

P-value from chi-square test of association between each variable and pre-pandemic versus post-pandemic with simulated p-value.